Arrivent Investigative Site

Memphis, Tennessee 38120

0 studies enrolling now · 1 studies all time

What they study most

Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations, Metastatic Non-Small Cell Lung Cancer

Studies at this site

• Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) — Running, not enrolling